Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients

Shuichiro Takashima, Toshihiro Miyamoto, Masanori Kadowaki, Yoshikiyo Ito, Takatoshi Aoki, Ken Takase, Takahiro Shima, Goichi Yoshimoto, Koji Kato, Tsuyoshi Muta, Motoaki Shiratsuchi, Katsuto Takenaka, Hiromi Iwasaki, Takanori Teshima, Tomohiko Kamimura, Koichi Akashi

研究成果: ジャーナルへの寄稿記事

4 引用 (Scopus)

抄録

Consolidation therapy for patients with multiple myeloma (MM) has been widely adopted to improve treatment response following autologous stem cell transplantation. In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM. VTD consisted of bortezomib at a dose of 1.3 mg/m2 and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. Peripheral neuropathy was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed. Very good partial response or better response (≥VGPR) rates before and after consolidation therapy were 54 and 79 %, respectively. Patients had a significant probability of improving from <VGPR before consolidation therapy to ≥VGPR after consolidation therapy (p = 0.041). The VTD regimen may be safe and effective as a consolidation therapy in the treatment of MM in Japanese population.

元の言語英語
ページ(範囲)159-164
ページ数6
ジャーナルInternational journal of hematology
100
発行部数2
DOI
出版物ステータス出版済み - 8 2014

Fingerprint

Thalidomide
Stem Cell Transplantation
Multiple Myeloma
Dexamethasone
Peripheral Nervous System Diseases
Therapeutics
Bortezomib
Neutropenia
Safety

All Science Journal Classification (ASJC) codes

  • Hematology

これを引用

Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. / Takashima, Shuichiro; Miyamoto, Toshihiro; Kadowaki, Masanori; Ito, Yoshikiyo; Aoki, Takatoshi; Takase, Ken; Shima, Takahiro; Yoshimoto, Goichi; Kato, Koji; Muta, Tsuyoshi; Shiratsuchi, Motoaki; Takenaka, Katsuto; Iwasaki, Hiromi; Teshima, Takanori; Kamimura, Tomohiko; Akashi, Koichi.

:: International journal of hematology, 巻 100, 番号 2, 08.2014, p. 159-164.

研究成果: ジャーナルへの寄稿記事

Takashima, Shuichiro ; Miyamoto, Toshihiro ; Kadowaki, Masanori ; Ito, Yoshikiyo ; Aoki, Takatoshi ; Takase, Ken ; Shima, Takahiro ; Yoshimoto, Goichi ; Kato, Koji ; Muta, Tsuyoshi ; Shiratsuchi, Motoaki ; Takenaka, Katsuto ; Iwasaki, Hiromi ; Teshima, Takanori ; Kamimura, Tomohiko ; Akashi, Koichi. / Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. :: International journal of hematology. 2014 ; 巻 100, 番号 2. pp. 159-164.
@article{414ae2bf5b3e4af8b923a012f1d28e1d,
title = "Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients",
abstract = "Consolidation therapy for patients with multiple myeloma (MM) has been widely adopted to improve treatment response following autologous stem cell transplantation. In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM. VTD consisted of bortezomib at a dose of 1.3 mg/m2 and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 {\%}), respectively, but drug dose reduction due to cytopenia was not required in any case. Peripheral neuropathy was common (63 {\%}), but severe grade 3-4 peripheral neuropathy was not observed. Very good partial response or better response (≥VGPR) rates before and after consolidation therapy were 54 and 79 {\%}, respectively. Patients had a significant probability of improving from <VGPR before consolidation therapy to ≥VGPR after consolidation therapy (p = 0.041). The VTD regimen may be safe and effective as a consolidation therapy in the treatment of MM in Japanese population.",
author = "Shuichiro Takashima and Toshihiro Miyamoto and Masanori Kadowaki and Yoshikiyo Ito and Takatoshi Aoki and Ken Takase and Takahiro Shima and Goichi Yoshimoto and Koji Kato and Tsuyoshi Muta and Motoaki Shiratsuchi and Katsuto Takenaka and Hiromi Iwasaki and Takanori Teshima and Tomohiko Kamimura and Koichi Akashi",
year = "2014",
month = "8",
doi = "10.1007/s12185-014-1611-1",
language = "English",
volume = "100",
pages = "159--164",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients

AU - Takashima, Shuichiro

AU - Miyamoto, Toshihiro

AU - Kadowaki, Masanori

AU - Ito, Yoshikiyo

AU - Aoki, Takatoshi

AU - Takase, Ken

AU - Shima, Takahiro

AU - Yoshimoto, Goichi

AU - Kato, Koji

AU - Muta, Tsuyoshi

AU - Shiratsuchi, Motoaki

AU - Takenaka, Katsuto

AU - Iwasaki, Hiromi

AU - Teshima, Takanori

AU - Kamimura, Tomohiko

AU - Akashi, Koichi

PY - 2014/8

Y1 - 2014/8

N2 - Consolidation therapy for patients with multiple myeloma (MM) has been widely adopted to improve treatment response following autologous stem cell transplantation. In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM. VTD consisted of bortezomib at a dose of 1.3 mg/m2 and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. Peripheral neuropathy was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed. Very good partial response or better response (≥VGPR) rates before and after consolidation therapy were 54 and 79 %, respectively. Patients had a significant probability of improving from <VGPR before consolidation therapy to ≥VGPR after consolidation therapy (p = 0.041). The VTD regimen may be safe and effective as a consolidation therapy in the treatment of MM in Japanese population.

AB - Consolidation therapy for patients with multiple myeloma (MM) has been widely adopted to improve treatment response following autologous stem cell transplantation. In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM. VTD consisted of bortezomib at a dose of 1.3 mg/m2 and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. Peripheral neuropathy was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed. Very good partial response or better response (≥VGPR) rates before and after consolidation therapy were 54 and 79 %, respectively. Patients had a significant probability of improving from <VGPR before consolidation therapy to ≥VGPR after consolidation therapy (p = 0.041). The VTD regimen may be safe and effective as a consolidation therapy in the treatment of MM in Japanese population.

UR - http://www.scopus.com/inward/record.url?scp=84905906856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905906856&partnerID=8YFLogxK

U2 - 10.1007/s12185-014-1611-1

DO - 10.1007/s12185-014-1611-1

M3 - Article

C2 - 24928523

AN - SCOPUS:84905906856

VL - 100

SP - 159

EP - 164

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -